Evaluating CS23546 for patients with advanced tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to assess the safety and tolerability of CS23546 in patients with advanced tumors through a single-arm, open-label phase I trial. It includes a dose escalation phase, where both single and multiple doses will be administered, followed by a dose expansion phase. The study will also evaluate the pharmacokinetic characteristics of CS23546 and determine the recommended phase 2 dose. Participants will need to provide tumor tissue samples for further analysis of specific biomarkers.

Why it matters

Who can join: the full rules

Key Inclusion Criteria:

1. Male or female and ≥18 years of age on day of signing informed consent.
2. Histologically or cytologically confirmed unresectable advanced recurrent/refractory solid tumor or lymphoma that is failure or or intolerant of all standard therapy or for which no standard therapy is available.
3. Individuals are required to provide tumor tissue samples for prospective detection of Programmed cell death 1 ligand 1 (PD-L1) expression and/or Microsatellite instability (MSI) / the DNA mismatch repair (MMR) status. Subjects who cannot be provided during the dose escalation phase will be evaluated by the researchers and sponsors before deciding whether to enroll.
4. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1.
5. Adequate organ function.
6. Life expectancy ≥12 weeks.
7. Dose expansion phase: Cohort 1, Subjects with urothelial carcinoma. Cohort 2, Subjects with Extranodal NK/T-cell lymphoma (NKTCL). Cohort 3, Subjects with soft tissue sarcoma. Cohort 4, Subjects with PD-L1 expression positive and/or microsatellite-instability-high (MSI-H) / mismatch-repair-deficient (dMMR) advanced solid tumors or lymphoma

Key Exclusion Criteria:

1. Received anti-tumor therapy (including but not limited to chemotherapy, targeted therapy, anti angiogenic therapy, immunotherapy, cell therapy, radiotherapy, tumor embolization, etc.) or experimental drugs/devices that have not been approved for marketing within 28 days before the first medication.
2. History of ≥ Grade 3 immune related Adverse Events (irAEs) or termination of treatment due to irAEs during prior treatment with Programmed death 1 (PD-1) /PD-L1 antibody.
3. Active autoimmune diseases present during the screening period and systemic treatment was received within 2 years before the first medication. Individuals who only require hormone replacement therapy (such as thyroxine, insulin, or physiological corticosteroids used for adrenal or pituitary insufficiency) can be enrolled.
4. Presence of central nervous system metastasis and/or meningeal metastasis.
5. Dose expansion phase: Subjects with solid tumors or lymphoma who have previously received PD-L1 inhibitors and belong to primary resistance.

Where it's running

• Sun Yat-sen University Cancer Cancer
  Guangzhou, China Recruiting

Study contacts

• Principal investigator: Huiqiang Huang, Ph.D. — Sun Yat-sen University Cancer Cancer
• Study coordinator: Xinhao Wang
• Email: xinhwang@chipscreen.com
• Phone: +86 0755-36993550

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• GW01-200 tablets in people with advanced cancers

  This early-phase study tests GW01-200 tablets in adults with advanced solid tumors or blood cancers to see if they are safe and how they behave in the body.

  Recruiting at 3 sites Phase 1 Groovy Medicine (Hangzhou) Ltd. · Beijing, Beijing Municipality and 2 other locations · NCT07629258

• SIBP-A10 injection for adults with advanced malignant tumors

  This trial will test whether SIBP-A10 injections are safe and tolerable and to identify the best dose for adults with advanced metastatic tumors.

  Recruiting Phase 1 Shanghai Institute Of Biological Products · Dalian, Liaoning · NCT07205198

• AL58805 treatment for people with advanced solid tumors.

  This Phase I dose-escalation trial will test different oral doses of AL58805 in people with advanced solid tumors who have exhausted standard treatment options.

  Recruiting Phase 1 Advenchen Laboratories, LLC · Changsha, Hunan · NCT07179081

• Testing MDX2004 at increasing doses in adults with advanced tumors

  This will test whether different doses of the experimental drug MDX2004 are safe and can shrink tumors in adults with advanced or metastatic cancer.

  Recruiting at 6 sites Phase 1/2 ModeX Therapeutics, An OPKO Health Company · Liverpool, New South Wales and 5 other locations · NCT07110584

• Personalized neoantigen vaccine combined with radiotherapy for advanced tumors

  This study is testing a personalized vaccine made from a patient's own tumor cells combined with radiotherapy to see if it can help people with advanced tumors that haven't responded to standard treatments.

  Recruiting Phase 2 The University of Hong Kong-Shenzhen Hospital · Shenzhen, Guangdong and 1 other locations · NCT06314087

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.